Enrolling by invitationNot applicableNCT06879665
TANDem-2: Closing the Gap to Interventions for TAND
Studying Tuberous sclerosis complex
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vrije Universiteit Brussel
- Principal Investigator
- Anna Jansen, MD, PhDVrije Universiteit Brussel
- Intervention
- Well-Beans for Caregivers Program(behavioral)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (2)
- TSC Alliance, Silver Spring, Maryland, United States
- Tuberous Sclerosis Australia, Beverly Hills, New South Wales, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06879665 on ClinicalTrials.govOther trials for Tuberous sclerosis complex
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07403266Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)Oils4Cure
- RECRUITINGNANCT06160310Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)David M. Ritter
- RECRUITINGPHASE2NCT05104983Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyDarcy Krueger
- RECRUITINGNANCT06764602Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous SclerosisIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGNANCT04198181The Effectiveness and Safety of Resective Epilepsy Surgery for TREBeijing Children's Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNovartis Pharmaceuticals
- RECRUITINGNANCT00001465Study of the Disease Process of LymphangioleiomyomatosisNational Heart, Lung, and Blood Institute (NHLBI)